Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.

With aging top dog Advair losing ground to generic and branded competitors alike, GlaxoSmithKline ($GSK) is grooming a lineup of respiratory up-and-comers to step in ...

Anoro Ellipta (umeclidinium/vilanterol) is a prescription drug that’s used to treat chronic obstructive pulmonary disease (COPD). Anoro Ellipta’s cost may depend ...

GlaxoSmithKline's ($GSK) respiratory franchise is going to have a lot of ground to make up once generic competition inevitably erodes sales of the $8.8 billion ...

GlaxoSmithKline and its partner Theravance recently scored a second victory in their quest to treat chronic obstructive pulmonary disease, commonly abbreviated as COPD -- an umbrella term that ...

Carl Battle has a big job on his hands managing pharmaceutical giant GlaxoSmithKline’s patent team. Michael Loney talks to him and some of his staff about bringing Anoro Ellipta to market, the dreaded ...

GlaxoSmithKline’s (GSK) chronic obstructive pulmonary disease (COPD) portfolio received a significant boost yesterday with the US approval of combination product Anoro Ellipta. The product combines ...

Mylan has become the first company to launch a generic version of GlaxoSmithKline's (GSK) big-selling respiratory drug Seretide in the UK. Seretide (salmeterol xinafoate/fluticasone propionate) – sold ...

Umeclidinium 62.5mcg, vilanterol 25mcg; per ­inhalation; dry pwd for oral inhalation. LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in ...